Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C1864663 (
HCC
)
2,985
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Using GGCX gene-specific real-time PCR, exon 2 deletion splice variant of vitamin K-dependent gamma-glutamyl carboxylase (GGCX) mRNA was identified in
HCC
cell lines. Expressions of wild type and exon 2 deletion variant of GGCX were analyzed with relevance to
DCP
production in
HCC
cell lines. Hep3B, HepG2, HuH1, HuH7, and PLC/PRF/5 produced
DCP
, while SK-Hep-1, HLE, HLF, and JHH1 produced no detectable level of
DCP
.
DCP
-producing cells expressed exon 2 deletion variant of GGCX mRNA and protein, while
DCP
-negative cells expressed no detectable level of exon 2 deletion variant of GGCX. These results suggest that exon 2 deletion splice variant of GGCX causes dysfunction of GGCX enzyme activity resulting in
DCP
production in
HCC
cell lines.
...
PMID:Exon 2 deletion splice variant of gamma-glutamyl carboxylase causes des-gamma-carboxy prothrombin production in hepatocellular carcinoma cell lines. 1938 45
The Authors make a review of the most important molecules used today for detecting and screening hepatocellular carcinoma, analyzing their known biological features, advantages and limits especially concerning differential diagnosis from cirrhosis and others diseases. AFP, AFP-L3,
DCP
, Alpha-1-fucosidase are analyzed and all the current knowledge reviewed, as well as focusing on possible future applications and results of combined determination (what about another word here: evaluation etc) in
HCC
. Additionally other more recent molecules showing promising future clinical application are cited.
...
PMID:Clinical biomarkers in hepatocellular carcinoma (HCC). 2003 69
Tumour markers could be helpful along the continuum of care for patients with hepatocellular carcinoma; however, there is insufficient data for routine use of most current biomarkers in clinical practice. Therefore, the backbone of early detection, diagnosis and treatment response for hepatocellular carcinoma remains imaging-based. Alpha fetoprotein is the best studied of all biomarkers and may be of benefit for early detection when used in combination with ultrasound. Several other biomarkers, including AFP-L3,
DCP
, osteopontin, and GP73, are also being evaluated for early detection of hepatocellular carcinoma in phase III biomarker studies. Serum and tissue-based biomarkers and genomics may aid in
HCC
diagnosis, prognosis, and treatment selection; however, further studies are needed to better characterize their accuracy and potential role in clinical practice.
...
PMID:Hepatocellular carcinoma tumour markers: current role and expectations. 2526 Mar 12